EDGAR Filing Documents for 0001144204-18-016884

Form 8-K - Current report:

SEC Accession No. 0001144204-18-016884

Filing Date

2018-03-26

Accepted

2018-03-26 15:56:52

Documents

Period of Report

2018-03-21

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 8-K	tv489507_8k.htm	8-K	25544
2	EXHIBIT 4.1	tv489507_ex4-1.htm	EX-4.1	80877
3	EXHIBIT 10.1	tv489507_ex10-1.htm	EX-10.1	399450
4	EXHIBIT 10.2	tv489507_ex10-2.htm	EX-10.2	445551
5	EXHIBIT 10.3	tv489507_ex10-3.htm	EX-10.3	73349
6	EXHIBIT 99.1	tv489507_ex99-1.htm	EX-99.1	14885
7	GRAPHIC	tv489507_ex10-2img1.jpg	GRAPHIC	27882
8	GRAPHIC	tv489507_ex99-1img1.jpg	GRAPHIC	15921
	Complete submission text file	0001144204-18-016884.txt		1101585

Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080

Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990

TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)